Leukemias and related diseases
within OPALE's research scope
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
- Myeloid sarcoma
- Leukemia predisposition syndromes
- Myeloproliferative Neoplasms (MPN), including: Chronic Myeloid Leukemia (CML), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), and others
- MDS/MPN syndromes, including: Chronic Myelomonocytic Leukemia (CMML), atypical CML, and others
- Mastocytosis
- Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions
- Pediatric and/or germline mutation-associated disorders, including: Juvenile Myelomonocytic Leukemia (JMML), Noonan syndrome, and others
- Myeloid proliferations associated with Down syndrome
- Acquired Bone Marrow Failure (BMF) syndromes, including: idiopathic Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Inherited BMF syndromes, including: Fanconi anemia, Blackfan-Diamond anemia, congenital dyskeratosis, Shwachman syndrome, congenital amegakaryocytic thrombocytopenia, MonoMAC/GATA2 syndrome
- Acute Lymphoblastic Leukemia (ALL), including: B-lineage ALL, T-lineage ALL and Lymphoblastic Lymphoma (T-LL)
- Acute undifferentiated leukemia or Mixed Phenotype Acute Leukemia (MPAL)
- Blastic Plasmacytoid Dendritic Cell Leukemia (BPDCL)
- Chronic Lymphocytic Leukemia (CLL)
- Waldenström Macroglobulinemia (WM)
A major medical need
Approximately 2.5 million individuals worldwide are affected by leukemia, making it the leading cancer among children. With around 475,000 new cases and 312,000 annual fatalities, leukemia stands as the deadliest among blood cancers. Adjusted for age, there is an anticipated rise in both incidence and mortality rates in the coming years. This underscores a critical medical need.
A dynamic Sector
Serving as a model for cancer research, leukemia stands out as an area of significant innovation: there are over 2,300 active clinical trials (sources: ICTRP Search Portal, ClinicalTrials.gov) in the field. Additionally, it was in leukemia (acute lymphoblastic leukemia) that the FDA approved the first CAR-T cell therapy, signifying a major technological breakthrough in the medical field. The treatment of leukemia represents a continuously growing market (source: Polaris Market Research), with an average annual growth rate of over 8.3% (reaching $14.6 billion in 2022, projected to reach $27.63 billion by 2030).